Treating tuberculous pleurisy with effusion by artificial pneumothorax

Area of Science:

• Pulmonology
• Infectious Diseases
• Medical Therapeutics

Background:

• Tuberculous pleurisy with effusion is a significant clinical challenge.
• Standard treatment involves antitubercular drugs and intrapleural interventions.
• Improving therapeutic efficacy and reducing complications remain key objectives.

Purpose of the Study:

• To evaluate the efficacy of artificial pneumothorax as an adjunct therapy for tuberculous pleurisy with effusion.
• To compare outcomes between patients receiving standard treatment and those receiving standard treatment plus artificial pneumothorax.

Main Methods:

• A randomized controlled trial involving 57 patients with tuberculous pleurisy with effusion.
• Patients were assigned to a control group (standard treatment) or a treatment group (standard treatment + artificial pneumothorax).
• Key metrics included fluid volume, frequency of drainage, time to resolution, and complication rates.

Main Results:

• The treatment group showed significantly reduced frequency and volume of pleural effusion compared to the control group.
• Artificial pneumothorax shortened the time required for fluid drainage and increased treatment efficiency (92.59% vs. 83.33%).
• This therapy was associated with increased intrapleural pressure, reduced parietal pleural leakage, and enhanced visceral pleural absorption, decreasing pleural adhesion rates.

Conclusions:

• Artificial pneumothorax is an effective adjunctive therapy for tuberculous pleurisy with effusion.
• It aids in reducing pleural fluid accumulation and accelerating its absorption.
• The technique helps prevent pleural adhesions, improving overall patient outcomes.